Effectiveness of Dex self-controlled sleep in recovery of sleep structure in patients with depression combined with sleep: relation to the antidepressant effect of Esk

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2400085177

Enrollment

Unknown

Registered

2024-06-01

Start date

2024-06-01

Completion date

Unknown

Last updated

2024-06-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression Comorbid Insomnia

Interventions

Trial group:Dexmedetomidine + esketamine

Eligibility

Sex/Gender

All

Age

12 Years to 80 Years

Inclusion criteria

Inclusion criteria: Meet the DMS-5 diagnostic criteria for insomnia disorder and depressive disorder; Voluntarily signed an informed consent form; Receiving rapid antidepressant treatment with Esk combined with Dex self-controlled sleep .

Exclusion criteria

Exclusion criteria: Severe cardiopulmonary, hepatic, renal, and cerebrovascular disease; History of hypersensitivity and contraindications to Esk and Dex; Sleep apnoea syndrome, restless legs syndrome were present or detected during sleep titration; Pregnant and lactating women.

Design outcomes

Primary

Measure	Time frame
sleep rhythm;Pittsburgh Sleep Quality Index Scale;Hamilton Depression Scale;	—

Secondary

Measure	Time frame
Hamilton Anxiety Scale;VAS of drug cravings;Dexmedetomidine dosage;heart rate;mean arterial pressure;oxygen saturation;	—

Countries

China

Contacts

Public ContactAn Jianxiong

Affiliated Hospital of Shandong Second Medical University (Affiliated Hospital of Weifang Medical University) University of Chinese Academy of Sciences, School of Medicine

anjianxiong@yeah.net+86 138 0128 1750

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026